Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
View Patent ↗The present invention relates to a novel class of hydroxamic acid derivatives carbamate, urea, amide and sulfonamide substitutions. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.
1. A compound represented by the following structural Formula:
wherein A is a group selected from:
wherein R 2 to R 6 , R 8 to R 10 and R 12 to R 16 are, independently of each other, a group selected from: substituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkylaryl, substituted C 1 -C 10 alkylcycloalkyl or substituted C 1 -C 10 alkylheterocyclyl; wherein the alkyl portion of the group is substituted with a substituent that is independently selected from —NR 20 C(═O)R 21 , —NR 20 C(═O)OR 21 , —C(═O)NR 21 R 22 , —NR 20 SO 2 R 21 or —NR 20 C(═O)NR 21 R 22 ;
R 1 , R 7 , R 11 and R 17 to R 20 are independently selected from hydrogen, unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
R 21 is selected from unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
R 22 is selected from hydrogen, unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
m, p and q are independently of each other 0;
n and r are independently of each other 0, 1 or 2;
t is 1 or 2;
or a stereoisomer, enantiomer, racemate, or pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein A is selected from
and all of the other substituents are as described in claim 1 .
3. The compound of claim 2 , wherein R 18 and R 19 are hydrogen.
4. The compound of claim 2 , wherein r is 0 and n is 0.
5. The compound of claim 2 , wherein R 2 to R 6 and R 12 to R 14 is independently selected from substituted —CH 2 -phenyl, substituted —CH 2 -naphthyl, substituted —CH 2 -benzyl, substituted —CH 2 -cyclohexyl, substituted —CH 2 -quinolinyl, substituted —CH 2 -isoquinolinyl, substituted —CH 2 -pyridyl, —CH(Ph) 2 , substituted —CH 2 CH 2 -phenyl, substituted —CH 2 CH 2 -naphthyl, substituted —CH 2 CH 2 -benzyl, substituted —CH 2 CH 2 -cyclohexyl, substituted —CH 2 CH 2 -quinolinyl, substituted —CH 2 CH 2 -isoquinolinyl, substituted —CH 2 CH 2 -pyridyl, substituted —CH 2 CH(Ph) 2 , substituted methyl, substituted ethyl, substituted propyl, substituted isopropyl, substituted butyl, substituted iso-butyl, substituted sec-butyl or substituted tert-butyl.
6. The compound of claim 2 , wherein the alkyl portion of the R 2 to R 6 and R 12 to R 14 is substituted with a substituent that is independently selected from —NR 20 C(═O)OR 21 or —NR 20 SO 2 R 21 .
7. The compound of claim 1 , wherein A is
R 1 and R 2 are as described in claim 1 .
8. The compound of claim 7 , wherein R 1 is hydrogen; and R 2 is substituted C 1 -C 10 alkylaryl.
9. The compound of claim 8 , wherein the alkyl portion of R 2 is substituted with a substituent selected from —NR 20 C(═O)OR 21 or —NR 20 SO 2 R 21 .
10. The compound of claim 9 , wherein R 20 is hydrogen and R 21 is unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl.
11. The compound of claim 1 , wherein A is
wherein R 5 is as described in claim 1 , n is 0 and m is 0, and R 17 is hydrogen.
12. The compound of claim 11 , wherein R 5 is substituted C 1 -C 10 alkylaryl.
13. The compound of claim 12 , wherein the alkyl portion of R 5 is substituted with a substituent selected from —NR 20 C(═O)OR 21 or —NR 20 SO 2 R 21 .
14. The compound of claim 13 , wherein R 20 is hydrogen and R 21 is unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl.
15. The compound of claim 1 represented by the following structural Formula:
wherein one of A 1 and A 2 is hydrogen and the other is a group selected from
wherein R 2 to R 6 , R 8 to R 10 and R 12 to R 16 are, independently of each other, a group selected from: substituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkylaryl, substituted C 1 -C 10 alkylcycloalkyl or substituted C 1 -C 10 alkylheterocyclyl; wherein the alkyl portion of the group is substituted with a substituent that is independently selected from —NR 20 C(═O)R 21 , —NR 20 C(═O)OR 21 , —C(═O)NR 21 R 22 , —NR 20 SO 2 R 21 or —NR 20 C(═O)NR 21 R 22 ;
R 1 , R 7 , R 11 and R 17 to R 20 are independently selected from hydrogen, unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
R 21 is selected from unsubstituted or substituted C 1 -C 10 alkyl, unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
R 22 is selected from hydrogen, unsubstituted or substituted C 1 -C 10 alkyl, Unsubstituted or substituted aryl, unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C 1 -C 10 alkylaryl, unsubstituted or substituted C 1 -C 10 alkylcycloalkyl, or unsubstituted or substituted C 1 -C 10 alkylheterocyclyl;
m, p and q are independently of each other 0;
n and r are independently of each other 0, 1 or 2;
t is 1 or 2;
or a stereoisomer, enantiomer, racemate, or pharmaceutically acceptable salt thereof.
16. The compound of claim 1 selected from:
tert-butyl [(1S)-1-benzyl-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)ethyl]carbamate;
N-hydroxy-6-{[{[(4-methylphenyl)sulfonyl]amino}(phenyl)acetyl]amino}-1-benzothiophene-2-carboxamide;
N-hydroxy-6-{[{[(4-methoxyphenyl)sulfonyl]amino}(phenyl)acetyl]amino}-1-benzothiophene-2-carboxamide;
tert-butyl [(1R)-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)-2-oxo-1-phenylethyl]carbamate;
benzyl [(1S)-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)-2-oxo-1-phenylethyl]carbamate;
benzyl [(1R)-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)-2-oxo-1-phenylethyl]carbamate;
or a stereoisomer, enantiomer, racemate, or pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.